Adebayo Atanda, MD
Advanced Heart Failure and Transplant Cardiology · Winchester, VANPI 1376939280
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $2,282 of the $3,290 with a category attached, or 69.3%. It is spread thinly across 17 manufacturers, the largest accounting for just 23.6%. Reporting peaked in 2023 at $1,715 and has fallen 65.9% since, to $585 in 2025. That places this record below the midpoint for advanced heart failure and transplant cardiology clinicians in VA, where the typical reported total is $4,498.
Across 63 payments — averaging $52.23 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Cvrx, Inc.$778
- Ancora Heart, Inc.$651
- Abbott$512
- Boehringer Ingelheim$342
- E.r. Squibb & Sons, L.L.C.$151
- Medtronic$142
- plus $714 from 11 others
What the payments were for
- Travel & lodging$1,00931%
- Food & beverage$2,28269%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Cvrx, Inc. | 7 | $778 |
| Ancora Heart, Inc. | 2 | $651 |
| Abbott | 4 | $512 |
| Boehringer Ingelheim | 17 | $342 |
| E.r. Squibb & Sons, L.L.C. | 3 | $151 |
| Medtronic(2 entities) | 3 | $142 |
| Abiomed | 1 | $142 |
| Novartis | 5 | $107 |
| Philips North America LLC | 4 | $103 |
| Pfizer | 6 | $100 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 3 | $61 |
| Novo Nordisk | 2 | $57 |
| Kestra Medical Technology Services, Inc. | 2 | $53 |
| Boston Scientific | 1 | $29 |
| Lantheus Medical Imaging, Inc. | 1 | $28 |
| Impulse Dynamics (USA) Inc. | 1 | $20 |
| Biotronik Inc. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$3,290 in reported general payments places this provider in the 35th percentile of 43 advanced heart failure and transplant cardiology providers in Virginia.
See all advanced heart failure and transplant cardiology providers in Virginia →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| VyndamaxTafamidis | 19 | $554,731 |
| JardianceEmpagliflozin | 230 | $305,179 |
| EntrestoSacubitril/Valsartan | 197 | $224,506 |
| EliquisApixaban | 97 | $110,302 |
| MounjaroTirzepatide | 42 | $52,355 |
| FarxigaDapagliflozin Propanediol | 22 | $32,115 |
| XareltoRivaroxaban | 12 | $16,535 |
| Metoprolol Succinate | 340 | $4,692 |
| Bumetanide | 75 | $3,892 |
| Potassium Chloride | 158 | $3,517 |
| Spironolactone | 317 | $2,094 |
| Torsemide | 63 | $2,052 |
| Ranolazine ErRanolazine | 22 | $2,001 |
| Furosemide | 324 | $1,678 |
| Isosorbide Dinitrate | 21 | $1,629 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerVyndamax, Eliquis | $100 | $665,033116 claims |
| Boehringer IngelheimJardiance | $342 | $305,179230 claims |
| NovartisEntresto | $107 | $224,506197 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 35th percentile of 43 advanced heart failure and transplant cardiology providers in Virginia.
Other advanced heart failure and transplant cardiology in Winchester
- Raveen ChawlaWinchester$22K
- Amin YehyaNorfolk$398K
- John HerreChesapeake$270K
- Raymond BenzaNorfolk$141K
- Palak ShahFalls Church$112K
- Zackary TushakNorfolk$92K
- Shashank DesaiFalls Church$80K
- Keyur ShahRichmond,$62K
- Mirnela BykuCharlottesville$62K
- Edward SaweyRichmond$35K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.